Inhalation

INH0219

Issue link: https://www.e-digitaleditions.com/i/1073928

Contents of this Issue

Navigation

Page 17 of 27

This section provides information that may be useful in research and development or manufacturing. Content is provided by the organizations listed. No endorsement or preference is intended. 16 February 2019 Inhalation Special Section Formulation development/ excipientS This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the organizations listed. No endorsement or preference is intended. Suite of pre-formulation and formulation capabilities Catalent provides a full suite of pre-formulation and formulation capabilities including screening of optimal API form (polymorph, salt, co-crystal); physicochemi- cal characterization; API compatibility in aqueous, pro- pellant-based and dry powder formulations; API perfor- mance optimization (solubility, viscosity, particle size reduction, droplet size distribution, etc.); nasal and oral inhalation dose forms (single or multidose); and addi- tional GLP and non-GLP development and characteri- zation services. Whether a single service or a turn-key development solution is required, Catalent Inhalation has the capability and expertise to advance product development, from feasibility studies through registra- tion and commercial supply. Catalent US: +1 888 SOLUTION www.catalent.com Bioperformance of inhaled therapeutics Strong bioperformance of your inhaled therapeutics is key to realizing optimal patient outcomes. Lonza sup- ports you in optimizing performance by leveraging unique capabilities and expertise in product design and particle engineering. You gain access to a large array of specialized tools, including micronization, spray-dry processing and nanocrystal technologies. Combined with formulation expertise for both small and large mol- ecules, specialized DPI capsules and finished product manufacturing capabilities to commercial scale, we bring your product from concept to market. Lonza–Capsugel US: +1 888 783-6361 www.pharma.lonza.com Inhalation Inhalation The Inhalation 123 e-newsletter previews upcoming conferences, highlights technical articles in Inhalation and more. Please watch for it in your inbox every other month. www.inhalationmag.com To see a sample, please click here. Sign up now by emailing your name, company name and email address to kmyers@cscpub.com.

Articles in this issue

Links on this page

view archives of Inhalation - INH0219